5/9/2025

Investors were underwhelmed by the solid earnings posted by Hologic, Inc. ( NASDAQ:HOLX ) recently. We have done some...

Source: Yahoo

5/8/2025

Hologic Inc. stock outperforms competitors on strong trading day

Source: MarketWatch

5/6/2025

Hologic's reduced debt, buybacks, and modest valuations make it appealing despite soft growth and pricey acquisitions. Click here to find out why HOLX is a Buy.

Source: SeekingAlpha

5/6/2025

Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.

Source: Yahoo

5/6/2025

For Q1 2025, Fidelity Mid-Cap Stock Fund returned -5.80%, modestly outperforming the -6.10% result of the benchmark. Click here to read the full commentary.

Source: SeekingAlpha

5/6/2025

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

Source: Yahoo

5/5/2025

Hologic Inc. stock underperforms Monday when compared to competitors

Source: MarketWatch

5/3/2025

Hologic ( NASDAQ:HOLX ) Second Quarter 2025 Results Key Financial Results Revenue: US$1.01b (down 1.2% from 2Q 2024...

Source: Yahoo

5/2/2025

Hologic Inc. stock underperforms Friday when compared to competitors

Source: MarketWatch

5/2/2025

Q2 2025 Hologic Inc Earnings Call

Source: Yahoo

5/2/2025

HOLX delivers earnings and revenue beat in the second quarter of fiscal 2025 amid macroeconomic turbulence.

Source: Yahoo

5/2/2025

REFINITIV STREETEVENTS EDITED TRANSCRIPT HOLX.OQ - Q2 2025 Hologic Inc Earnings Call EVENT DATE/TIME: MAY 01, 2025 / 8:30PM GMT ...

Source: Finnhub

5/2/2025

Despite a slight revenue decline, Hologic Inc (HOLX) demonstrates resilience with strong diagnostics growth and strategic financial positioning.

Source: Yahoo

5/1/2025

Medical equipment maker Hologic lowered its fiscal 2025 profit forecast, citing uncertainty around the tariffs imposed by U.S. President Donald Trump's administration, sending the company's shares down 3% after the bell on Thursday. The Marlborough, Massachusetts-based company makes test kits, diagnostic products and cancer screening devices. The company is lowering its adjusted profit outlook based on "tariffs and geopolitical conditions", said Chief Financial Officer Karleen Oberton.

Source: Yahoo

5/1/2025

Medical technology company Hologic (NASDAQ:HOLX) met Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 1.2% year on year to $1.01 billion. On the other hand, next quarter’s revenue guidance of $1.01 billion was less impressive, coming in 2% below analysts’ estimates. Its non-GAAP profit of $1.03 per share was 1.4% above analysts’ consensus estimates.

Source: Yahoo

5/1/2025

While the top- and bottom-line numbers for Hologic (HOLX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Source: Yahoo

5/1/2025

Hologic (HOLX) delivered earnings and revenue surprises of 0.98% and 0.34%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Source: Yahoo

5/1/2025

Hologic, Inc. (NASDAQ:HOLX) Q2 2025 Earnings Conference Call May 1, 2025 4:30 PM ETCompany ParticipantsMike Watts - Corporate VP, IRSteve MacMillan -...

Source: SeekingAlpha

5/1/2025

The Marlborough, Massachusetts-based company said it had a loss of 8 cents per share. Earnings, adjusted for one-time gains and costs, were $1.03 per share. The results topped Wall Street expectations.

Source: Yahoo

5/1/2025

MARLBOROUGH, Mass., May 01, 2025--Hologic Announces Financial Results for Second Quarter of Fiscal 2025

Source: Yahoo